3 completed, 1 not yet recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
Follow TNF Pharmaceuticals, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Isomyosamine in Reducing Inflammation and Treating Muscle Loss in Older Adults After Hip or Thigh Bone Fractures Isomyosamine 250mg, Placebo 250 mg - Sarcopenia in Elderly, Frailty | Phase 2 | Not yet recruiting | TNF Pharmaceuticals, Inc. | 60 | 2025-05-01 | 2025-04-24 |
| Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty MYMD-1 600MG, MYMD-1 750mg, MYMD-1 900mg - Sarcopenia, Frailty | Phase 2 | Completed | TNF Pharmaceuticals, Inc. | 40 | 2022-02-01 | 2023-10-30 |
| Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects MYMD-1, Placebo - Hashimoto Disease | Phase 1 | Completed | TNF Pharmaceuticals, Inc. | 32 | 2021-04-26 | 2023-03-27 |
| Single Ascending-dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male Adult Subjects MyMD1, Placebo - Undefined | Phase 1 | Completed | TNF Pharmaceuticals, Inc. | 40 | 2019-06-11 | 2020-04-16 |
Frailty (2) · Hashimoto Disease (2) · Sarcopenia (2) · Femoral Fractures (1) · Hip Fractures (1)
isomyosmine (2)
United States (3)
Leonard Dunn, MD (2) · Art Simon, PhD (1) · Jeremy Walston, MD (1) · Leonard J Dunn, MD (1) · Lon Lynn, DO (1)